| Bioactivity | BF844 mitigate hearing loss associated with USH3 (usher syndrome type III) mutation CLRN1 (clarin-1)N48K. BF844 induces CLRN1N48K transportes to the plasma membrane. BF844 shows significantly preserves hearing in vivo[1]. |
| Invitro | BF844 (compound 3) (0.846 µM) effectively inhibits HSP60 activity (87.07±27.70% inhibition) and moderately inhibited HSP90 (40.06±19.10% inhibition)[1].BF844 (2.90 µM; 24 h) induces about 6% of total CLRN1N48K to be transported to the plasma membrane in C1, D1, D6 cells[1].BF844 (2.90 µM; 24 h) effectively increases the amount of non-glycosylated CLRN1 and non-glycosylated CLRN1 is effectively transported to the plasma membrane in C1 and D1 cells[1]. |
| In Vivo | BF844 shows good penetration into the retina and cochlea in vivo[1].BF844 (10 mg/kg; i.p.) shows significantly preserves hearing in Tg;KI/KI mice[1]. Animal Model: |
| Name | BF844 |
| CAS | 1404506-35-9 |
| Formula | C21H19ClN4O |
| Molar Mass | 378.85 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Alagramam KN, et al. A small molecule mitigates hearing loss in a mouse model of Usher syndrome III. Nat Chem Biol. 2016 Jun;12(6):444-51. |